NEW YORK (GenomeWeb) – NanoString Technologies reported after the close of the market Tuesday that its second quarter revenues increased 51 percent year over year.

Shares in NanoString fell in Wednesday morning trade, however, on concerns about reimbursement for its Prosigna test.

The Seattle-based molecular diagnostics firm brought in total revenues of $10.9 million for the three months ended June 30, up from $7.2 million in the second quarter of 2013. It beat the average Wall Street estimate of $10.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.